Search

Krystal Biotech Inc

Отворен

СекторЗдравеопазване

356.36 -3.46

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

352.32

Максимум

371.96

Ключови измерители

By Trading Economics

Приходи

-1.2M

55M

Продажби

2.9M

119M

P/E

Средно за сектора

44.829

56.659

EPS

1.79

Марж на печалбата

45.938

Служители

295

EBITDA

2.9M

66M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+8.4% upside

Дивиденти

By Acuity

Следващи печалби

2.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

31M

10B

Предишно отваряне

359.82

Предишно затваряне

356.36

Настроения в новините

By Acuity

15%

85%

20 / 339 Класиране в Healthcare

Krystal Biotech Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.09.2026 г., 19:36 ч. UTC

Krystal Biotech Inc shares are higher today, reaching a session peak before retracing some gains. The stock remains above its 20-day moving average.

1.09.2026 г., 23:41 ч. UTC

Krystal Biotech Inc shares are lower in after-market hours, declining from earlier highs despite being above the 20-day moving average. No specific news was identified.

31.08.2026 г., 20:02 ч. UTC

Krystal Biotech Inc's shares are higher today, showing notable intraday volatility and remaining above their 20-day moving average. No specific news was identified.

25.08.2026 г., 20:07 ч. UTC

Krystal Biotech Inc shares are higher today, benefiting from easing Treasury yields and strong momentum, despite no specific company news driving the move.

24.08.2026 г., 19:16 ч. UTC

Krystal Biotech Inc's shares are lower today, continuing a decline since Friday. Market focus remains on upcoming economic events amid inflation concerns.

21.08.2026 г., 21:01 ч. UTC

Krystal Biotech shares are lower in after-market trading, reflecting a modest decline since Friday's close amid limited price fluctuations.

20.08.2026 г., 21:01 ч. UTC

Krystal Biotech Inc shares are higher in after-market trading, maintaining a position above their 20-day moving average without any specific news to explain the rise.

19.08.2026 г., 20:02 ч. UTC

Correlated Moves

Shares rise amid positive momentum in biotechnology sector.

14.08.2026 г., 19:46 ч. UTC

News

RBC Capital initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, boosting shares higher since Thursday's close.

13.08.2026 г., 19:46 ч. UTC

Correlated Moves

Krystal Biotech Inc shares are lower, reflecting a broader decline in the biotechnology sector and trading below their 20-day moving average.

12.08.2026 г., 20:52 ч. UTC

Krystal Biotech Inc shares declined during after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

11.08.2026 г., 21:01 ч. UTC

Krystal Biotech Inc. shares rose in after-market trading, reaching a high of 1.23% above Tuesday's close, despite remaining below its 20-day moving average.

7.08.2026 г., 19:26 ч. UTC

Krystal Biotech Inc shares are higher during Friday's session, reflecting a gain since Thursday's close. No specific news was identified to explain the movement.

6.08.2026 г., 19:26 ч. UTC

Shares of Krystal Biotech Inc. are lower today, trading near the lower end of their one-month range and below the 20-day moving average.

5.08.2026 г., 19:52 ч. UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

4.08.2026 г., 20:04 ч. UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

3.08.2026 г., 23:06 ч. UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

31.07.2026 г., 23:06 ч. UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

30.07.2026 г., 19:39 ч. UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

29.07.2026 г., 20:04 ч. UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

28.07.2026 г., 20:03 ч. UTC

Event
Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

27.07.2026 г., 22:02 ч. UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

24.07.2026 г., 19:11 ч. UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

23.07.2026 г., 10:01 ч. UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

22.07.2026 г., 19:26 ч. UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

21.07.2026 г., 18:36 ч. UTC

News
Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

20.07.2026 г., 21:21 ч. UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Сравнение с други в отрасъла

Ценова промяна

Krystal Biotech Inc Прогноза

Ценова цел

By TipRanks

8.4% нагоре

12-месечна прогноза

Среден 402.67 USD  8.4%

Висок 474 USD

Нисък 361 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Krystal Biotech Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

7

Купи

1

Задържане

0

Продай

Настроение

By Acuity

20 / 339 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
help-icon Live chat